Here is a brief preview of this blast: Lilly announced it has entered into a new agreement with Dexcom to integrate Dexcom CGMs into Lilly's personalized diabetes management system. Recall, Lilly and Dexcom first entered into their connected care partnership back in 2017, following Lilly's announcement on its connected ecosystem. Below, FENIX provides potential insights into the updated Lilly/Dexcom partnership.
About The Author
Matthew Maryniak
President of Fenix Group International
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.